Diabete Mellitus
104
17
25
35
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.0%
1 terminated out of 104 trials
97.2%
+10.7% vs benchmark
8%
8 trials in Phase 3/4
3%
1 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 35 completed trials
Clinical Trials (104)
Choices and Experiences Around Closed-loop Therapy in Type 1 Diabetes
Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab
Developing a Colonoscopy Preparation Protocol for Patients With Diabetes
Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus
Empowerment-Based Health Education and Type 2 Diabetes Mellitus
FSL2 Post Approval Study for Pediatric and Young Adults Patients
The Effect Of Color Rotation Technique Training On İnsülin Self-management İn Diabetic Patients.
Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes
Total Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy
The Impact of Social Worker Referrals on Diabetes and Loneliness
Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters
AI-Based Diabetic Foot Recurrence Cohort
"Erectile Function After PCI in MI and Non-MI Patients"
Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts
Telemedicine-Based Behavioral Intervention to Improve Outcomes Among Diabetic Patients
Omega-3 Pufa and Aspirin as Adjunctive Therapy in Treatment of Smoker Patients With Stage Iii Periodontitis
Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers
Duodenal ReCET as an Early Treatment for Type 2 DM
The Role of Inflammatory Biomarkers in Preventing Deep Sternal Wound Infections After Sternotomy
Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients